TUD | Center for Regenerative Therapies Dresden (CRTD)
Loading...
Prof. Albert @mareikealbert.bsky.social is part of MICRO-NEST, a new international consortium. Backed by €6 million Horizon Europe grant 🇪🇺, it combines multidisciplinary expertise to study early markers of autism spectrum disorders.
Read more ➡️ tud.link/319gn4
#CMCBnews @tudresden.bsky.social
Join #MSc Physics of Life @tudresden.bsky.social and help shape the future of #Biophysics!
Learn from the world-class scientists of the CMCB and @poldresden.bsky.social
More about the program ➡️ tud.link/3wz553
Don't miss the testimonials from our graduates ⤵️
#studyinGermany #MastersProgram
New funding for Korean-German collaboration! 🇰🇷 🤝🇩🇪
Backed by the @dfg.de, the Albert group @mareikealbert.bsky.social @tudresden.bsky.social partners with Korean researchers to study how epigenetics and the extracellular matrix shape the human cortex 🧠 🧬
Read more ➡️ tud.link/qqvtcv
#CMCBnews
“Super macrophages” against cancer 🧬
Prof. Michael Sieweke, Dr. Anke Fuchs, and Dr. Angela Jacobi are developing a new immune cell therapy targeting solid tumors. Backed by €2.5M from the EIC, StemPhage aims to bring this approach closer to clinical use 🔬
Read more ➡️ tud.link/vwwmxg
#CMCBnews
YouTube video by Center for Molecular and Cellular Bioengineering
TUD | Center for Regenerative Therapies Dresden (CRTD)
TUD | Center for Regenerative Therapies Dresden (CRTD)
TUD | Center for Regenerative Therapies Dresden (CRTD)
TUD | Center for Molecular and Cellular Bioengineering (CMCB)
Fantastic news! 🥳
@tudresden.bsky.social continues as University of Excellence!
The project builds on decades of research at the Sieweke Lab @siewekelab.bsky.social and combines it with cell production expertise of Dr. Anke Fuchs.
🔬✨ For #IWD2026, we’re highlighting the voices of #WomenInScience!
In our short interview with Dr. Anna Czarkwiani @aniaczark.bsky.social shares what might surprise teenagers about a career in research and the skills that shaped her journey.
Read more ➡️ tud.link/yjts9v
#CMCB #TUDresden
Im Rahmen der Studie Fr1da: „Typ-1-Diabetes früh erkennen, früh gut behandeln“ vom @crtd-tud.bsky.social & dem Universitätsklinikum Dresden können Familien ihre Kinder im Alter von zwei bis zehn Jahren auf ein Frühstadium von Typ-1-Diabetes testen lassen. 🧸 #Diabetes
ℹ️ tu-dresden.de/tu-dresden/n...